Literature DB >> 28626273

Combined Antipsychotics and Electroconvulsive Therapy in an Acutely Psychotic Patient with Treatment-resistant Schizophrenia.

Ruth Rayikanti1, Iga Lentowicz1, Badari Birur1, Li Li1.   

Abstract

Treatment of patients with Treatment-resistant Schizophrenia (TRS), who fail to respond to multiple antipsychotic trials, including clozapine (CLZ), is challenging. Several alternative strategies are reported in studies, one of which includes augmenting antipsychotics (AP) with Electroconvulsive therapy (ECT). We discuss a case of an acutely psychotic patient with TRS who responded effectively and sustained remission to this strategy which was ECT combined with two AP, CLZ and aripiprazole. Notable improvement in clinical and cognitive outcomes was seen with just five right unilateral ECT sessions, CLZ titrated up to 62.5 mg/d and aripiprazole 20 mg/d with no adverse effects. Nine days into the psychiatric hospitalization, patient had decreased total scores on the Positive and Negative Syndrome Scale by 44% and an improved score on the St. Louis University Mental Status Exam by increasing from 3 to 22. This case report suggests that a subgroup of patients with TRS could benefit from a trial of adjunct ECT combined with AP to achieve a rapid alleviation of positive and negative symptoms which allows patients to have greater functional stability.

Entities:  

Keywords:  aripiprazole; clozapine; electroconvulsive therapy; treatment-resistant schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28626273      PMCID: PMC5472173     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  14 in total

Review 1.  ECT for treatment-resistant schizophrenia: a response from the far East to the UK. NICE report.

Authors:  Worrawat Chanpattana; Chittaranjan Andrade
Journal:  J ECT       Date:  2006-03       Impact factor: 3.635

Review 2.  Practice guideline for the treatment of patients with schizophrenia, second edition.

Authors:  Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

3.  Defining treatment refractoriness in schizophrenia.

Authors:  H Y Meltzer
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

Review 4.  The social and economic burden of treatment-resistant schizophrenia: a systematic literature review.

Authors:  James L Kennedy; C Anthony Altar; Danielle L Taylor; Irina Degtiar; John C Hornberger
Journal:  Int Clin Psychopharmacol       Date:  2014-03       Impact factor: 1.659

5.  Lifetime prevalence of psychotic and bipolar I disorders in a general population.

Authors:  Jonna Perälä; Jaana Suvisaari; Samuli I Saarni; Kimmo Kuoppasalmi; Erkki Isometsä; Sami Pirkola; Timo Partonen; Annamari Tuulio-Henriksson; Jukka Hintikka; Tuula Kieseppä; Tommi Härkänen; Seppo Koskinen; Jouko Lönnqvist
Journal:  Arch Gen Psychiatry       Date:  2007-01

6.  Combined ECT and neuroleptic therapy in treatment-refractory schizophrenia: prediction of outcome.

Authors:  W Chanpattana; M L Chakrabhand
Journal:  Psychiatry Res       Date:  2001-12-15       Impact factor: 3.222

7.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

8.  Electroconvulsive therapy for treating schizophrenia: a chart review of patients from two catchment areas.

Authors:  Diana Kristensen; Jeanett Bauer; Ida Hageman; Martin Balslev Jørgensen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-12-05       Impact factor: 5.270

9.  Augmentation of antipsychotics with electroconvulsive therapy in treatment-resistant schizophrenia patients with dominant negative symptoms: a pilot study of effectiveness.

Authors:  Tomasz Pawełczyk; Emilia Kołodziej-Kowalska; Agnieszka Pawełczyk; Jolanta Rabe-Jabłońska
Journal:  Neuropsychobiology       Date:  2014-10-24       Impact factor: 2.328

Review 10.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.

Authors:  Alkomiet Hasan; Peter Falkai; Thomas Wobrock; Jeffrey Lieberman; Birte Glenthoj; Wagner F Gattaz; Florence Thibaut; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2012-07       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.